SCHEMBL1551603

SCHEMBL1551603

Cc1ccc(C(C)(C)C)cc1Nc1nc(Cl)nc2ncn(C)c12

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 4/20 0.60
PSEN2 P49810 4/20 0.60
APH1B Q8WW43 4/20 0.60
NCSTN Q92542 4/20 0.60
APH1A Q96BI3 4/20 0.60
PSENEN Q9NZ42 4/20 0.60
P2RX7 Q99572 4/20 0.36
NLRP3 Q96P20 1/20 0.33
MEN1 O00255 1/20 0.33
CRHBP P24387 1/20 0.33
KMT2A Q03164 1/20 0.33
CRHR2 Q13324 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
YTHDC1 Q96MU7 1/20 0.33
BRAF P15056 5/20 0.33
LCK P06239 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7940703 0.78 PSEN1 (0.71) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2520184 0.78 PSEN1 (0.70) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2522680 0.77 PSEN1 (0.80) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2518947 0.77 PSEN1 (0.66) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL7930859 0.77 PSEN1 (0.62) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2524363 0.77 PSEN1 (0.71) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL7931101 0.77 PSEN1 (0.77) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL7940852 0.77 PSEN1 (0.67) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2524311 0.77 PSEN1 (0.66) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL7941001 0.77 PSEN1 (0.68) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110251172-A1 PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME CORP. 2011-10-13 US disclosed
US-20110251172-A1 PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME CORP. 2011-10-13 US disclosed
EP-2312945-A1 PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE Merck Sharp & Dohme Corp. (US) 2011-04-27 EP disclosed
WO-2010019392-A1 PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME CORP. (US) 2010-02-18 WO disclosed
WO-2010019392-A1 PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME CORP. (US) 2010-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251172-A1 PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE BACE1, APP, PSEN1 PSEN1 3/4885PSEN2 4/4885APH1B 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.